Condition
Neuroendocrine Tumor G2
Total Trials
3
Recruiting
0
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
3 of 0 completed with results
Key Signals
3 with results
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (2)
Trial Status
Active Not Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT00569127Phase 3Active Not Recruiting
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
NCT01841736Phase 2Active Not Recruiting
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
NCT03375320Phase 3Active Not Recruiting
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Showing all 3 trials